Evidence map›Paper›PMID 36157689›Full record

ArticleCase reports in oncology

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation.

Ken Saijo, Hiroo Imai, Hiromichi Katayama, Fumiyoshi Fujishima, Kenichi Nakamura, Yuki Kasahara, Kota Ouchi, Keigo Komine, Hidekazu Shirota, Masanobu Takahashi and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ken SaijoDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Hiroo ImaiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Hiromichi KatayamaDepartment of Urology, Tohoku University Hospital, Sendai, Japan.
Fumiyoshi FujishimaDepartment of Pathology, Tohoku University Hospital, Sendai, Japan.
Kenichi NakamuraClinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
Yuki KasaharaDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Kota OuchiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Keigo KomineDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Hidekazu ShirotaDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Masanobu TakahashiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Chikashi IshiokaDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 18-year-old Japanese man was diagnosed with an undifferentiated sarcoma of the spermatic cord, with multiple distant metastases to the lungs and bones. The patient received doxorubicin-based standard chemotherapy. Although the chemotherapy was effective, it induced severe adverse events, which led to treatment discontinuation. A comprehensive genomic profiling test using resected tumor tissue revealed the

Indexed as

BRAF V600EComprehensive genomic profilingDabrafenibSarcomaTrametinib

Identifiers

PMID36157689
PMCPMC9459523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.